Last reviewed · How we verify
50% magnesium sulphate
At a glance
| Generic name | 50% magnesium sulphate |
|---|---|
| Also known as | magnesium sulfate |
| Sponsor | Queen Sirikit National Institute of Child Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hypotension
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
- Comparison of Fentanyl and Magnesium to Control Reflex Hemodynamics in Patients Aged 50 and Older (NA)
- Magnesium vs. Dexmedetomidine in TURBT Under Spinal Anesthesia (NA)
- Comparison Between Total Intravenous Anesthesia With Magnesium Sulphate Versus Total Intravenous Anesthesia With Dexmedetomidine in Patients Undergoing Lumbar Spine Surgeries (PHASE3)
- Post Operative Shivering Following Anesthesia (NA)
- Comparison of Nebulized Ketamine With Nebulized Magnesium Sulfate for the Prevention of Postoperative Sore Throat (NA)
- Comparison Between Intrathecal Magnesium Sulphate & Dexmedetomidine in DHS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 50% magnesium sulphate CI brief — competitive landscape report
- 50% magnesium sulphate updates RSS · CI watch RSS
- Queen Sirikit National Institute of Child Health portfolio CI